3 Stocks That May Be Trading Below Their Estimated Value In February 2025

As global markets continue to navigate a complex landscape marked by rising U.S. inflation and near-record highs for major stock indexes, investors are keenly observing the interplay between economic data and policy decisions. With growth stocks outperforming value shares and inflationary pressures influencing rate expectations, identifying undervalued stocks that may offer potential value becomes increasingly significant in such an environment.

Top 10 Undervalued Stocks Based On Cash Flows

Name	Current Price	Fair Value (Est)	Discount (Est)
Provident Financial Services (NYSE:PFS)	US$18.48	US$36.92	49.9%
Hibino (TSE:2469)	¥2770.00	¥5502.15	49.7%
Power Wind Health Industry (TWSE:8462)	NT$110.50	NT$220.75	49.9%
Smurfit Westrock (NYSE:SW)	US$55.32	US$110.32	49.9%
América Móvil. de (BMV:AMX B)	MX$14.90	MX$29.71	49.9%
Com2uS (KOSDAQ:A078340)	₩48250.00	₩96043.49	49.8%
F-Secure Oyj (HLSE:FSECURE)	€1.706	€3.41	49.9%
AIMECHATEC (TSE:6227)	¥3785.00	¥7563.15	50%
Likewise Group (AIM:LIKE)	£0.185	£0.37	49.8%
EKINOPS (ENXTPA:EKI)	€3.285	€6.57	50%

Click here to see the full list of 918 stocks from our Undervalued Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Angelalign Technology (SEHK:6699)

Overview: Angelalign Technology Inc. is an investment holding company that focuses on researching, developing, designing, manufacturing, and marketing clear aligner treatment solutions in the People’s Republic of China with a market cap of approximately HK$10.03 billion.

Operations: The company's revenue primarily comes from its Dental Equipment & Supplies segment, which generated CN¥1.72 billion.

Estimated Discount To Fair Value: 17.7%

Angelalign Technology is trading at HK$60, below its estimated fair value of HK$72.93, offering potential undervaluation based on cash flows. Despite a low forecasted return on equity of 6.7% in three years, the company's earnings are expected to grow significantly at 69.6% annually, outpacing the Hong Kong market's growth rate of 11.7%. However, profit margins have declined from last year due to large one-off items impacting financial results.

• Insights from our recent growth report point to a promising forecast for Angelalign Technology's business outlook.
• Delve into the full analysis health report here for a deeper understanding of Angelalign Technology.

Jinhui Mining Incorporation (SHSE:603132)

Overview: Jinhui Mining Incorporation Limited is involved in the exploration, mining, processing, and sale of lead, zinc, silver, and other mineral resources in China with a market cap of CN¥10.93 billion.

Operations: Jinhui Mining Incorporation Limited generates revenue through its activities in the exploration, mining, processing, and sale of lead, zinc, silver, and other mineral resources within China.

Estimated Discount To Fair Value: 13.3%

Jinhui Mining Incorporation is trading at CN¥11.46, slightly below its estimated fair value of CN¥13.21, suggesting potential undervaluation based on cash flows. The company's earnings and revenue are forecast to grow significantly at 37.1% and 36.2% per year respectively, outpacing the Chinese market averages. However, the dividend yield of 3.58% is not well covered by free cash flows, and the company maintains a high level of debt which may impact financial flexibility.

• Our earnings growth report unveils the potential for significant increases in Jinhui Mining Incorporation's future results.
• Get an in-depth perspective on Jinhui Mining Incorporation's balance sheet by reading our health report here.

HangzhouS MedTech (SHSE:688581)

Overview: Hangzhou AGS MedTech Co., Ltd. focuses on the research, development, production, sale, and service of endoscopic surgery equipment and accessories in China with a market cap of approximately CN¥4.85 billion.

Operations: HangzhouS MedTech generates revenue through the development and sale of endoscopic surgery equipment and accessories within China.

Estimated Discount To Fair Value: 46.5%

HangzhouS MedTech is trading at CN¥61.39, significantly below its fair value estimate of CN¥114.84, highlighting potential undervaluation based on cash flows. The company has completed a share buyback of 401,400 shares for CNY 30.97 million, which may indicate confidence in its valuation. Revenue growth is expected to outpace the market at 26.9% annually, though earnings growth forecasts are lower than the market average at 22.3% per year.

• The growth report we've compiled suggests that HangzhouS MedTech's future prospects could be on the up.
• Navigate through the intricacies of HangzhouS MedTech with our comprehensive financial health report here.

Make It Happen

• Access the full spectrum of 918 Undervalued Stocks Based On Cash Flows by clicking on this link.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com